Solventum Seeks Offers for Health Information Systems Business in Potential Divestiture
Solventum is reportedly collecting offers for its Health Information Systems business, signaling a possible portfolio review without confirming a buye…
Bristol Myers Squibb Jumps 6.5% After Twin Phase 3 Trial Wins
Bristol Myers Squibb rose 6.5% after two positive Phase 3 readouts, but mixed insider and guru positioning adds a note of caution.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Vaxcyte Stock Surges After $1.15 Billion Raise for VAX-31 Vaccine Program
Vaxcyte’s $1.15 billion public offering strengthens its balance sheet, supports VAX-31 development and reduces near-term…
STERIS’s $2.1 Billion Xodus Medical Deal Tests Healthcare M&A Appetite
STERIS’s $2.1 billion Xodus Medical agreement puts financing, dilution and medical-device M&A appetite under the microsc…
Bristol Myers Squibb Stock Jumps on Rare Double Phase 3 Success
BMY shares rose 5.7% to 6.5% after two positive Phase 3 readouts, putting pipeline value and analyst targets back in foc…
Lipocine’s TLANDO Approval Opens a New Canadian Test for $LPCN
Health Canada’s approval of TLANDO gives Lipocine a Canadian commercial pathway, with Verity Pharma targeting a launch b…
Merck and Moderna’s Positive Phase 3 Cancer Vaccine Data Reshape the Oncology Trade
Merck’s Keytruda gains and Moderna’s 9% stock pop highlight two distinct oncology narratives: established scale and pote…
Pfizer’s TUKYSA FDA Approval Opens a New Frontline Breast Cancer Growth Opportunity
Pfizer’s frontline FDA approval for TUKYSA could broaden its oncology opportunity as investors assess the company’s post…
Perrigo Takeover Chatter Puts PRGO Shares on M&A Watch
Reported takeover interest has put Perrigo and its PRGO shares in the spotlight, but no buyer, offer price or deal terms…
Moderna and Merck Cancer Vaccine Trial Success Puts MRNA and MRK in Focus
Phase 3 melanoma data from Moderna and Merck may strengthen the case for mRNA oncology and add strategic value to Keytru…
Teva Hits 52-Week High as FDA Clears First Once-Monthly Schizophrenia Injection
Teva’s WELTRUZA approval gives investors a potential specialty-medicine catalyst as the company advances its branded-pha…